PMID- 38058468
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231208
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 27
IP  - 1
DP  - 2024 Jan
TI  - Efficacy and outcome analysis: Combination of Endostar and chemotherapy as a 
      neoadjuvant treatment of stage IIIA/IIIB squamous cell lung cancer.
PG  - 23
LID - 10.3892/ol.2023.14156 [doi]
LID - 23
AB  - Patients with stage IIIA/IIIB squamous non-small cell lung cancer (SqCLC) are 
      particularly challenging to treat with a poor 5-year survival rate and new 
      treatment strategies are needed. In the present study, a retrospective, 
      single-center study was conducted to explore the efficacy and safety of Endostar 
      combined with chemotherapy as the neoadjuvant treatment in patients with stage 
      IIIA/IIIB SqCLC. A total of 27 patients with locally advanced SqCLC treated with 
      Endostar combined with chemotherapy as neoadjuvant therapy from January 1, 2017 
      to December 31, 2019 at the Zhejiang Cancer Hospital (Hangzhou, China) were 
      included. Short-term efficacy, rate of surgical resection, long-term outcome and 
      adverse events were analyzed. After treatment with Endostar combined with 
      chemotherapy, 37% of the patients underwent surgery and the radical resection 
      rate was 90%. The objective response rate was 63% for the total population and 
      80% for patients who received surgery. Of note, 100% of the patients achieved 
      disease control after treatment with Endostar combined with chemotherapy. In 
      patients who underwent surgical resection, postoperative pathology showed that 
      100% of the patients achieved pathological downstaging. Furthermore, 1 (10%) 
      patient showed a pathological complete response after surgery. The median 
      progression-free survival was 13.5 months and overall survival was 27.9 months 
      for the total cohort. The most common adverse events (AEs) were anemia (69.4% of 
      patients), followed by hypertension (29.6% of patients). Most of the AEs were 
      grade 1-2 and only 4 patients (14.8%) developed grade 3-4 AEs. Endostar combined 
      with chemotherapy was well-tolerated and showed promising efficacy in patients 
      with stage IIIA/IIIB SqCLC. Further prospective studies are warranted to explore 
      its value as a neoadjuvant therapy.
CI  - Copyright: (c) Cao et al.
FAU - Cao, Feiyi
AU  - Cao F
AD  - Department of Medical Oncology, Postgraduate Training Base Alliance of Wenzhou 
      Medical University (Zhejiang Cancer Hospital), Hangzhou, Zhejiang 310022, P.R. 
      China.
AD  - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of 
      Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China.
FAU - Ding, Sijie
AU  - Ding S
AD  - Department of Tumor Radiotherapy and Chemotherapy, Lishui Central Hospital, 
      Lishui, Zhejiang 323000, P.R. China.
FAU - Gu, Cuiping
AU  - Gu C
AD  - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of 
      Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China.
FAU - Zhou, Yao
AU  - Zhou Y
AD  - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of 
      Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China.
FAU - Hong, Wei
AU  - Hong W
AD  - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of 
      Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China.
FAU - Jin, Ying
AU  - Jin Y
AD  - Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of 
      Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P.R. China.
AD  - Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, Zhejiang 310022, P.R. 
      China.
LA  - eng
PT  - Journal Article
DEP - 20231116
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC10696629
OTO - NOTNLM
OT  - anti-angiogenesis therapy
OT  - combined chemotherapy
OT  - neoadjuvant therapies
OT  - non-small cell lung carcinoma
OT  - squamous cell lung carcinoma
COIS- All authors declare that they have no competing interests.
EDAT- 2023/12/07 06:42
MHDA- 2023/12/07 06:43
PMCR- 2023/11/16
CRDT- 2023/12/07 04:04
PHST- 2023/04/27 00:00 [received]
PHST- 2023/10/20 00:00 [accepted]
PHST- 2023/12/07 06:43 [medline]
PHST- 2023/12/07 06:42 [pubmed]
PHST- 2023/12/07 04:04 [entrez]
PHST- 2023/11/16 00:00 [pmc-release]
AID - OL-27-1-14156 [pii]
AID - 10.3892/ol.2023.14156 [doi]
PST - epublish
SO  - Oncol Lett. 2023 Nov 16;27(1):23. doi: 10.3892/ol.2023.14156. eCollection 2024 
      Jan.